Sandoz Enters into a Commercialization and License Agreement with Bio-Thera to Commercialize BAT1706- a Proposed Biosimilar Avastin (bevacizumab)
Shots:
- Bio-Thera to receive an up front- milestones along with royalties on product sales & will be responsible for the development- manufacturing- supply of BAT1706
- Sandoz to get rights for the commercialization of the therapy upon approval in the US- EU- Canada- and other countries. Bio-Thera’s BAT1706 has completed extensive biosimilar studies- including a global P-III study
- Bevacizumab is a humanized mAb that targets VEGF. Avastin has been approved in the US and EU to treat multiple types of cancer
Ref: Bio-Thera | Image: Reuters
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.
